These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36994198)

  • 41. The impact of adjuvant EGFR-TKIs and 14-gene molecular assay on stage I non-small cell lung cancer with sensitive EGFR mutations.
    Jiang Y; Lin Y; Fu W; He Q; Liang H; Zhong R; Cheng R; Li B; Wen Y; Wang H; Li J; Li C; Xiong S; Chen S; Xiang J; Mann MJ; He J; Liang W
    EClinicalMedicine; 2023 Oct; 64():102205. PubMed ID: 37745018
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC.
    Jung HA; Lim J; Choi YL; Lee SH; Joung JG; Jeon YJ; Choi JW; Shin S; Cho JH; Kim HK; Choi YS; Zo JI; Shim YM; Park S; Sun JM; Ahn JS; Ahn MJ; Han J; Park WY; Kim J; Park K
    Clin Cancer Res; 2022 Oct; 28(19):4312-4321. PubMed ID: 35838647
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of adjuvant EGFR inhibitors and impact of clinical factors in resected
    Li M; Hou X; Lin S; Zheng L; Liang J; Chen J; Wang N; Zhang B; Chen L
    Future Oncol; 2022 Mar; 18(9):1159-1169. PubMed ID: 35109665
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
    Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
    J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Survival analysis of patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitor (TKI) treatment: A multi-center retrospective study.
    Shi Q; Guan M; Wang Y; Xu C; Tang L; Fu W; Bi M; Sun X; Gu K; Pang D
    Thorac Cancer; 2018 Feb; 9(2):278-283. PubMed ID: 29266865
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in
    Li Q; Ma L; Qiu B; Wen Y; Liang W; Hu W; Chen N; Zhang T; Xu S; Chen L; Guo M; Zhao Y; Liu S; Guo J; Wang J; Wang S; Wang X; Pang Q; Long H; Liu H
    Curr Oncol; 2021 Apr; 28(2):1424-1436. PubMed ID: 33916930
    [TBL] [Abstract][Full Text] [Related]  

  • 47. EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada.
    Sara Kuruvilla M; Liu G; Syed I; Gwadry-Sridhar F; Sheffield BS; Sachdeva R; Pencz A; Zhan L; Hueniken K; Patel D; Balaratnam K; Khan K; Grant B; Noy S; Singh K; Liu L; Rakibuz-Zaman M; Moldaver D; Kate Shanahan M; Cheema PK
    Lung Cancer; 2022 Nov; 173():58-66. PubMed ID: 36152478
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
    Yue D; Xu S; Wang Q; Li X; Shen Y; Zhao H; Chen C; Mao W; Liu W; Liu J; Zhang L; Ma H; Li Q; Yang Y; Liu Y; Chen H; Wang C
    Lancet Respir Med; 2018 Nov; 6(11):863-873. PubMed ID: 30150014
    [TBL] [Abstract][Full Text] [Related]  

  • 49. When to add anti-angiogenesis drugs to EGFR-mutated metastatic non-small cell lung cancer patients: a real-world study from Taiwan.
    Chen CL; Wang ST; Liao WC; Chen CH; Tu CY; Chen HJ; Hsia TC; Cheng WC
    BMC Cancer; 2022 May; 22(1):571. PubMed ID: 35599308
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study.
    Li N; Ou W; Ye X; Sun HB; Zhang L; Fang Q; Zhang SL; Wang BX; Wang SY
    Ann Surg Oncol; 2014 Jun; 21(6):2091-6. PubMed ID: 24585406
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study.
    Yu X; Si J; Wei J; Wang Y; Sun Y; Jin J; Zhang X; Ma T; Song Z
    Cancer Med; 2023 Mar; 12(5):5630-5638. PubMed ID: 36380563
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differential effects of adjuvant EGFR tyrosine kinase inhibitors in patients with different stages of non-small-cell lung cancer after radical resection: an updated meta-analysis.
    Lu D; Wang Z; Liu X; Feng S; Dong X; Shi X; Wang H; Wu H; Xiong G; Wang H; Cai K
    Cancer Manag Res; 2019; 11():2677-2690. PubMed ID: 31037035
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical efficacy and safety of adjuvant EGFR-TKIs for resected stage IB lung adenocarcinoma: A real-world study based on propensity score matching.
    Shen L; Guo J; Zhang W; Zhang L; Liu X; Wang T; Zhang T; Liang C; Liu Y
    Cancer Med; 2023 Sep; 12(18):18470-18478. PubMed ID: 37559419
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy.
    Feng S; Wang Y; Cai K; Wu H; Xiong G; Wang H; Zhang Z
    PLoS One; 2015; 10(10):e0140794. PubMed ID: 26474174
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical outcomes in patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer in South Western Sydney Local Health District.
    Ding PN; Roberts TL; Chua W; Becker TM; Descallar J; Yip PY; Bray V
    Intern Med J; 2017 Dec; 47(12):1405-1411. PubMed ID: 28742280
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer.
    Takenaka T; Takenoyama M; Yamaguchi M; Toyozawa R; Inamasu E; Kojo M; Toyokawa G; Yoshida T; Shiraishi Y; Morodomi Y; Hirai F; Taguchi K; Shimokawa M; Seto T; Ichinose Y
    Eur J Cardiothorac Surg; 2015 Mar; 47(3):550-5. PubMed ID: 24894095
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-World Treatment Patterns and Survival Among Patients with Stage I-III, Non-Squamous, Non-Small Cell Lung Cancer Receiving Surgery as Primary Treatment.
    Seung SJ; Moldaver D; Hassan S; Syed I; Shanahan M; Liu G
    Oncol Ther; 2024 Jun; 12(2):311-326. PubMed ID: 38485888
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A real-world study of dacomitinib in later-line settings for advanced non-small cell lung cancer patients harboring EGFR mutations.
    Li HS; Zhang JY; Yan X; Xu HY; Hao XZ; Xing PY; Wang Y
    Cancer Med; 2022 Feb; 11(4):1026-1036. PubMed ID: 35023313
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
    Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
    Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with
    Shibaki R; Akamatsu H; Kato T; Nishino K; Okada M; Mitsudomi T; Wakuda K; Yoshimura K; Yamamoto N; Nakagawa K
    Ther Adv Med Oncol; 2021; 13():1758835920987647. PubMed ID: 33613698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.